Disease areas
More about our work in Immunology
We strive to accelerate innovation of transformational medicines that deliver more years of life and quality of life for patients and families living with cancer.
Redefining the Future of Cancer Treatment
We are united around our mission to redefine the future of cancer treatment. Our goal is to help people facing cancer live longer, better lives. Our hope is fueled by the dream of a future free from cancer.
Unlocking hope
Addressing the unmet medical needs of cancer patients
Today, our oncology researchers passionately strive to turn cancers into manageable chronic conditions or even curable diseases.
Tomorrow, our hope is fueled by the dream of a future free from cancer. We are determined to shift the treatment paradigm of cancer.
The urgency for effective, broadly accessible treatment options and novel therapies is paramount, as the outlook for patients is often grim, with survival measured in months rather than years. That’s what fuels our ambition to redefine the future of cancer treatment.
SPEED
Speed is critical for cancer patients who cannot afford to wait to receive treatment
URGENCY
Urgent need for effective, broadly accessible treatment options and novel therapies is paramount
Driving pipeline growth and leveraging cross-modality synergies
Differentiated Technology Platforms
Small Molecules
– Excellence, speed, agility: fully-integrated, end-to-end in-house capabilities
– Best-in-class strategy: validated targets to develop differentiated medicines
– 25 years of experience: enhanced by external partnerships
Cell Therapy
– Scalable, decentralized, fast: fresh, fit, stem-like, early memory cells within a median vein-to-vein time of seven days
– High-yielding discovery engine: multi-targeting, next-generation cell therapies
– Diversify and grow: through partnerships and M&A
Our focus in oncology
Our current work is focused on the following hematological cancers for patients in need of additional and improved treatment options:
Non-Hodgkin’s lymphoma (NHL)
Chronic lymphocytic leukemia (CLL), including Richter transformation (RT)
Multiple myeloma (MM)
Shifting the paradigm
Cell therapy
In 2022, we entered the field of cell therapy and antibody-therapy research and development through the acquisitions of CellPoint (in the Netherlands) and Abound Bio (in the U.S). The transactions provide us with end-to-end capabilities in cell therapy development and offer the potential for a paradigm shift in the space through the implementation of a breakthrough, decentralized manufacturing model and cutting-edge fully human antibody-based capabilities to design next-generation cell therapies.
Did you know?
~ 70%* of eligible patients do not receive CAR-T due to:
Limited capacity
Complex logistics
Restricted access
*Evidence-Based Oncology, October 2023, Volume 29, Issue 8
Fast, fresh, fit and stem-like
Our innovative approach to T-cell manufacturing near the point of care
Galapagos’ innovative decentralized cell therapy manufacturing platform has the potential for the administration of fresh, fit, stem-like, early memory cells within a median vein-to-vein time of seven days, greater physician visibility, and improved patient experience.
The platform consists of an end-to-end xCellit® workflow management and monitoring software system, a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon®) and a proprietary quality control testing and release strategy.
Cell therapy in 7 days vein-to-vein
*GMP production at a compliant manufacturing facility located at the clinic premises or in close proximity to the clinic; The Cocoon® Platform is a registered trademark of Lonza Group AG
Decentralized manufacturing, close to patients
Our approach is based on a decentralized, functionally closed, automated manufacturing platform for cell therapies (using Lonza’s Cocoon® Platform). Discover more about it!
Factsheet
Our commitment in oncology
Do you need everything in one place about our efforts in redefining the future of cancer treatments?
Pioneer with us in Oncology
This is your call for purpose!
Do you want to pioneer for patients in Oncology? Discover our vacancies!
Partnerships
Work with us!
We combine internal and external innovation to add new capabilities, technologies and product candidates. Let’s start #PioneeringForPatients, together!